Form 4: Neurogene Inc. Executive Cobb Receives Stock Options and Common Stock
SEC Form 4 Filing
Neurogene Inc.'s Chief Scientific Officer, Stuart Cobb, reports acquisition of stock options and common stock.
Summary
- On March 13, 2024, Stuart Cobb, the Chief Scientific Officer of Neurogene Inc., acquired 20,391 shares of common stock.
- Cobb also acquired options to purchase 34,450 shares of common stock at an exercise price of $36.06.
- The options vest over time, starting with 1/4 on March 13, 2025, and then 1/48 monthly thereafter, contingent on continued service to Neurogene.
Sentiment
Score: 7
Explanation: The sentiment is neutral to slightly positive. It reflects standard executive compensation practices, suggesting confidence in the company's future.
Positives
- The acquisition of stock and options by a key executive like the Chief Scientific Officer can be seen as a positive sign, indicating confidence in the company's future prospects.
Future Outlook
The vesting schedule of the options suggests a long-term commitment from the executive to the company.
Industry Context
Stock option grants are a common practice in the biotechnology industry to incentivize and retain key personnel.
Comparison to Industry Standards
- Stock option grants are a typical component of executive compensation packages in the biotech industry, often benchmarked against peer companies of similar size and stage of development.
- Companies like BioMarin Pharmaceutical and Sarepta Therapeutics also utilize stock options extensively to align executive interests with shareholder value.
- The vesting schedule is fairly standard, with back-ended vesting to encourage long-term commitment.
Stakeholder Impact
- The stock option grant could potentially align the executive's interests more closely with those of the shareholders.
Key Dates
| Date | Description |
|---|---|
| 03/13/2024 | Date of transaction: Acquisition of common stock and stock options. |
| 03/13/2025 | First vesting date for 1/4 of the stock options. |
| 03/13/2034 | Expiration date of the stock options. |
| 03/14/2024 | Date of signature for the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.